Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer

Abstract

BackgroundTrastuzumab (Herceptin® [H]) is the standard of care for HER2-positive locally advanced/metastatic breast cancer and gastric/gastroesophageal junction (GEJ) cancer. However, there is a paucity of data available on long-term H treatment of patients. The Rollover Protocol (ROP) Study was conducted to report safety data for patients with HER2-positive locally advanced/metastatic breast and gastric/GEJ cancer who have received long-term H therapy (≥ 5 years and ≥ 3 years for breast and gastric/GEJ cancer, respectively).MethodsThe ROP Study was a single-arm, multicenter, international continuation trial of H in patients who had previously completed a global Roche-sponsored trial with H therapy, had stable disease, and were receiving H at the end of the lead-in trial. Patients with chronic heart failure during the lead-in trial could be included following a risk–benefit analysis. The primary objectives were to provide H therapy to patients with HER2-overexpressing locally advanced/metastatic breast or gastric/GEJ cancer at the end of the lead-in study, and to follow the long-term outcomes and long-term overall safety in these patients.ResultsTwenty-five of 69 patients enrolled in the ROP Study received long-term H therapy (19 breast cancer and 6 gastric/GEJ cancer). The median duration of H treatment for patients with breast cancer was 8 years 7 months, and 5 years 2 months for patients with gastric/GEJ cancer. The cardiac status of the patients remained stable over time, with no serious cardiac adverse events or marked changes in left ventricular ejection fraction (LVEF). The median overall worst LVEF measurement was 57.0%, and no patients experienced an LVEF of < 45% (range 47–63%). There were no serious adverse events related to study treatment.ConclusionsThese results suggest that H has an acceptable safety profile and was well tolerated in patients who received long-term H therapy (≥ 5 years and ≥ 3 years for breast and gastric/GEJ cancer, respectively). Further investigation and reporting of long-term H therapy would be valuable.Trial registrationThis study was retrospectively registered on March 24, 2016 with Clinicaltrials.gov, number NCT02721641.Electronic supplementary materialThe online version of this article (10.1186/s12885-018-4183-2) contains supplementary material, which is available to authorized users.

Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities

“…Anti-HER-2 treatment is approved long-term for breast cancer, stomach cancer, and gastroesophageal junction cancer with HER-2 overexpression/amplification. (22)(23)(24) Several anti-HER2 clinical trials and case reports show that HER2 is a promising target in BTC, but anti-HER2 agents are still not approved for routine administration in BTC. (25) EGFR alterations were identified in 2.7% (5 of 186) of our cases.…”

Identification of circulating tumor DNA using a targeted 545‑gene next generation sequencing panel in patients with gastric cancer

“…One crucial purpose of molecular diagnosis in patients with cancer is to determine sensitive drug targets (34), including HER2, which could be specifically bound by herceptin, which is a monoclonal antibody used in anticancer therapy (35). The present study identified two true-positive HER2 CNV in patients.…”

Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium

“…Furthermore, these studies showed that Trastuzumab was effective when used in monotherapy as well as in combination with platinum compounds (Baselga et al, 1996 ; Pegram et al, 1998 ). The effectiveness and safety of Trastuzumab have made it the gold standard treatment for women with metastatic breast cancer, alone or in combination with paclitaxel or doxorubicin, and for patients affected by HER2-positive metastatic gastric carcinoma (Müller et al, 2018 ). Finally, in 2013 a conjugated monoclonal antibody was approved, named Trastuzumab-emtansine.…”